Across TCGA pan-cancer cohorts, PNMA6A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PNMA6A data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PNMA6A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PNMA6A expression acts as an unfavorable survival marker.
UCEC are the cancer types where PNMA6A Mutation most reproducibly stratifies survival.